Genenta Science S.p.A. (SAEN) income statement
SAENNasdaqBiological Products, (No Diagnostic Substances)
$0.58+0.00 (+0.85%)
Close on Nov 18, 2026Market cap $13.64MP/E –Yield –
Genenta Science S.p.A. financial ratios
See a number that looks wrong?
Close on Nov 18, 2026Market cap $13.64MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Returns on capital | ||||||||
| Return on equity | -38.0% | -54.1% | -45.2% | -24.2% | -20.5% | -32.9% | -34.3% | – |
| Return on assets | -28.0% | -48.0% | -41.8% | -23.1% | -19.2% | -32.0% | – | – |
| Return on tangible assets | -28.0% | -48.0% | -41.8% | -23.1% | -19.2% | -32.0% | – | – |
| Return on capital employed | -31.1% | -58.6% | -45.2% | -31.5% | -21.0% | -36.9% | – | – |
| NOPAT | -5.22M | -7.71M | -9.27M | -8.72M | -4.49M | -4.42M | -3.65M | – |
| Cash flow quality | ||||||||
| OCF / Net income | 1.05 | 0.70 | 0.96 | 0.88 | 1.26 | 1.08 | 0.54 | – |
| FCF / OCF | 100.1% | 100.1% | 100.1% | 100.4% | 100.1% | 100.3% | – | – |
| FCF / Net income | 1.05 | 0.70 | 0.96 | 0.88 | 1.26 | 1.08 | – | – |
| FCF / EBITDA | 104.6% | 64.2% | 96.0% | 67.5% | 122.6% | 108.5% | – | – |
| Unlevered free cash flow | -6.88M | -6.24M | -11.22M | -7.45M | -6.97M | -6.07M | – | – |
| Levered free cash flow | -6.88M | -6.24M | -11.22M | -7.45M | -6.97M | -6.07M | – | – |
| Efficiency | ||||||||
| CapEx to OCF | -0.11% | -0.07% | -0.12% | -0.36% | -0.13% | -0.35% | – | – |
| CapEx to depreciation | 0.27 | 0.10 | 0.32 | 4.41 | 1.84 | 10.98 | – | – |
| Liquidity | ||||||||
| Current ratio | 14.16 | 6.89 | 12.25 | 14.53 | 34.15 | 7.09 | – | – |
| Quick ratio | 14.16 | 6.89 | 12.25 | 14.53 | 34.15 | 7.09 | – | – |
| Cash ratio | 13.29 | 6.05 | 10.83 | 13.65 | 32.81 | 6.63 | – | – |
| Working capital | 27.86M | 12.37M | 19.52M | 29.54M | 37.62M | 14.20M | – | – |
| Net current asset value | 19.93M | 12.14M | 19.34M | 29.42M | 37.59M | 14.18M | – | – |
| Leverage | ||||||||
| Assets to equity | 1.46 | 1.19 | 1.09 | 1.07 | 1.03 | 1.16 | – | – |
| Intangibles to total assets | – | – | – | 0.26% | – | – | – | – |
| Per share | ||||||||
| EPS (basic) | – | – | -0.64 | -0.47 | -0.37 | – | – | – |
| EPS (diluted) | -0.33 | -0.49 | -0.64 | -0.47 | -0.37 | – | – | – |
| Book value per share | 0.93 | 0.68 | 1.12 | 1.71 | 2.13 | 0.83 | – | – |
| Tangible book value per share | 0.93 | 0.68 | 1.12 | 1.70 | 2.13 | 0.83 | – | – |
| Cash per share | 1.20 | 0.69 | 1.03 | 1.64 | 2.04 | 0.85 | – | – |
| Operating cash flow per share | -0.29 | -0.34 | -0.62 | -0.41 | -0.38 | -0.33 | – | – |
| Free cash flow per share | -0.29 | -0.34 | -0.62 | -0.41 | -0.38 | -0.33 | – | – |
| CapEx per share | 0.0003 | 0.0002 | 0.0008 | 0.0015 | 0.0005 | 0.0011 | – | – |
| Valuation at period end | ||||||||
| Market cap | 28.53M | 79.56M | 90.17M | 100.19M | 199.69M | – | – | – |
| Enterprise value | 7.76M | 62.06M | 65.60M | 63.10M | 182.18M | – | – | – |
| P/B | 1.3x | 6.4x | 4.4x | 3.2x | 5.1x | – | – | – |
| P/TBV | 1.3x | 6.4x | 4.4x | 3.2x | 5.1x | – | – | – |
| P/OCF | -4.2x | -12.7x | -8.0x | -13.5x | -28.7x | – | – | – |
| EV/OCF | -1.1x | -9.9x | -5.9x | -8.5x | -26.2x | – | – | – |
| Earnings yield | -22.9% | -11.2% | -12.9% | -8.5% | -2.8% | – | – | – |
| FCF yield | -24.1% | -7.8% | -12.4% | -7.4% | -3.5% | – | – | – |
| Per employee | ||||||||
| Total employees | 13 | 13 | 14 | 9 | 7 | 7 | 7 | 7 |
| Operating profit per employee | -507.98K | -751.10K | -838.07K | -1.23M | -812.47K | -798.60K | -660.64K | – |
| Net income per employee | -502.29K | -685.58K | -831.82K | -941.97K | -789.90K | -798.86K | -656.82K | – |
| Free cash flow per employee | -528.89K | -480.36K | -801.34K | -827.26K | -995.31K | -866.49K | – | – |
| Growth | ||||||||
| EBIT 1Y growth | 32.4% | 16.8% | -6.2% | -94.2% | -1.7% | -20.9% | – | – |
| EBITDA 1Y growth | 32.3% | 16.9% | -5.9% | -94.2% | -1.7% | – | – | – |
| Net income 1Y growth | 26.7% | 23.5% | -37.4% | -53.3% | 1.1% | -21.6% | – | – |
| Diluted EPS 1Y growth | 32.7% | 23.4% | -36.2% | -27.0% | – | – | – | – |
| Operating cash flow 1Y growth | -10.1% | 44.3% | -51.0% | -6.6% | -15.1% | -142.7% | – | – |
| Free cash flow 1Y growth | -10.1% | 44.3% | -50.7% | -6.9% | -14.9% | – | – | – |
| CapEx 1Y growth | 70.7% | -67.6% | -49.1% | 200.5% | -56.8% | – | – | – |
| CapEx 3Y CAGR | -34.4% | -20.8% | -12.9% | – | – | – | – | – |
| CapEx 5Y CAGR | -18.2% | – | – | – | – | – | – | – |
| Total assets 1Y growth | 115.1% | -33.7% | -33.2% | -16.5% | 128.7% | – | – | – |
| Total assets 3Y CAGR | -1.6% | -28.2% | 8.5% | – | – | – | – | – |
| Total assets 5Y CAGR | 12.7% | – | – | – | – | – | – | – |
| Total equity 1Y growth | 74.8% | -38.8% | -34.4% | -19.9% | 156.5% | -19.6% | 137.7% | – |
| Total equity 3Y CAGR | -11.1% | -31.5% | 10.5% | 18.2% | 69.9% | – | – | – |
| Total equity 5Y CAGR | 7.6% | -7.9% | 20.8% | – | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.